目的评价抗CD25单克隆抗体对肾移植受者术后早期CD4+CD25high调节性T细胞(CD4+CD25 high Treg)的影响。方法2007年2-9月接受初次亲属活体供肾移植的受者41例,根据是否使用抗CD25单克隆抗体(商品名daclizumab)分为抗体组(21例)和对照组(2...目的评价抗CD25单克隆抗体对肾移植受者术后早期CD4+CD25high调节性T细胞(CD4+CD25 high Treg)的影响。方法2007年2-9月接受初次亲属活体供肾移植的受者41例,根据是否使用抗CD25单克隆抗体(商品名daclizumab)分为抗体组(21例)和对照组(20例)。其中抗体组在肾移植术前2h及术后第14天分别给予抗CD25单抗各50mg。在移植前及移植后第13、17、60天分别留取肝素抗凝外周血15ml。应用流式细胞仪测定两组受者外周血CD4+T细胞和CD4+CD25 high Treg比例的变化,半定量RT-PCR检测CD25 mRNA的表达变化。结果肾移植术后13、17、60d抗体组的CD25+T细胞占CD4+T细胞的比例(20%±8%、13%±7%、24%±9%)低于对照组(45%±6%、41%±5%、40%±6%),差异有统计学意义(P<0.05)。抗体组术后第17天CD4+CD25 high Treg占CD4+T细胞的比例为4.40%±0.26%,明显低于对照组(8.56%±0.36%,P<0.01);而术后13、60d抗体组CD4+CD25 high Treg所占比例分别为7.00%±0.47%、3.75%±0.19%,与对照组(分别为8.04%±0.32%、3.66%±0.31%)比较差异无统计学意义(P>0.05)。抗体组CD25 mRNA相对表达水平在给予第二次抗体前(术后第13天)为1.65±0.22,术后第17天为1.84±0.27,两者间差异无统计学意义(P>0.05)。对照组术后第17天CD25 mRNA相对表达水平为1.70±0.23,与抗体组比较差异无统计学意义(P>0.05)。结论两剂共100mg抗CD25单抗仅一过性地降低CD4+CD25 high Treg,不会影响其活化扩增,无损于术后早期的免疫耐受诱导及维持。展开更多
背景与目的:有关非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)与免疫抑制状态的研究引起人们的关注。调节T细胞(regulatory T cell,Treg)是免疫抑制细胞,Treg与淋巴瘤之间的关系存在争议。本研究检测初诊NHL患者及正常人外周血Treg...背景与目的:有关非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)与免疫抑制状态的研究引起人们的关注。调节T细胞(regulatory T cell,Treg)是免疫抑制细胞,Treg与淋巴瘤之间的关系存在争议。本研究检测初诊NHL患者及正常人外周血Treg水平,探讨外周血Treg与NHL的关系。方法:选取中山大学肿瘤防治中心2006年12月至2008年3月收治的99例初诊NHL患者及31例体检正常的健康成人的外周血标本,采用流式细胞仪联合标记CD4、CD25、CD127检测NHL患者及健康成人外周血CD4+CD25highCD127low Treg水平并进行分析。结果:正常人外周血CD4+CD25highCD127low Treg水平为8.07±1.90,初诊NHL患者外周血CD4+CD25highCD127low Treg水平为11.20±4.40,差异具有统计学意义(P<0.001)。NHL患者外周血Treg水平在男性患者中比在女性患者中高,差异具有统计学意义(P=0.030);在有吸烟和/或嗜酒组比在无吸烟和/或嗜酒组高,差异具有统计学意义(P=0.045);而NHL患者外周血Treg水平与年龄、分期、IPI评分、B症状、巨大包块、LDH水平、病理亚型、近期疗效、HBV感染等之间的相关检验无统计学意义。在弥漫大B细胞性淋巴瘤中分析结果亦相似。结论:初诊NHL患者体内存在免疫抑制,有吸烟和/或嗜酒等不良嗜好的NHL患者Treg水平较无不良嗜好者高,Treg水平与NHL的疾病状态无关。展开更多
The proportion and changes of CD4^＋CD25^high regulatory T cells （Trs） in peripheral blood of non-small cell lung cancer （NSCLC） patients were analyzed and their clinical significance explored. The peripheral bloo...The proportion and changes of CD4^＋CD25^high regulatory T cells （Trs） in peripheral blood of non-small cell lung cancer （NSCLC） patients were analyzed and their clinical significance explored. The peripheral blood was collected from 61 patients with NSCLC and 15 healthy controls. By using monoclonal antibodies, the blood samples were evaluated with the flow cytometry for lymphocyte subsets （CD3^＋, CD4^＋ and CD8^＋） and CD4^＋CD25^high Tr cells. The results showed that the proportion of CD4^＋CD25^high Tr cells in NSCLC group was significantly higher than in control group [（4.36 ±2.07） % vs （2.04±1.03） %, P〈0.01]. The proportion of CD4^＋CD25^ high Tr cells in late stage was higher than that in early stage [stages Ⅰ ＋Ⅱ （2.264±0.6） %; stage Ⅲ（3.284± 1.38） %; stage IV （6.06 4±4.08） %] （P〈0.05）. Kaplan-Meier survival analysis revealed that the prognosis of the patients who had higher proportion of CD4^＋CD25^high Tr cells in peripheral blood was worse （P=0.0026）. In conclusion, the relative increase in CD4^＋CD25^high Tr cells in peripheral blood may be related to im- munosuppression and tumor progression in patients with NSCLC. This finding suggests that CD4^＋CD25^high Tr cells in peripheral blood of NSCLC may be positive for prognosis analysis. The use of depletion of the CD4^＋CD25^high Tr cell therapy to treat NSCLC patients may be an effective strategy.展开更多
文摘目的评价抗CD25单克隆抗体对肾移植受者术后早期CD4+CD25high调节性T细胞(CD4+CD25 high Treg)的影响。方法2007年2-9月接受初次亲属活体供肾移植的受者41例,根据是否使用抗CD25单克隆抗体(商品名daclizumab)分为抗体组(21例)和对照组(20例)。其中抗体组在肾移植术前2h及术后第14天分别给予抗CD25单抗各50mg。在移植前及移植后第13、17、60天分别留取肝素抗凝外周血15ml。应用流式细胞仪测定两组受者外周血CD4+T细胞和CD4+CD25 high Treg比例的变化,半定量RT-PCR检测CD25 mRNA的表达变化。结果肾移植术后13、17、60d抗体组的CD25+T细胞占CD4+T细胞的比例(20%±8%、13%±7%、24%±9%)低于对照组(45%±6%、41%±5%、40%±6%),差异有统计学意义(P<0.05)。抗体组术后第17天CD4+CD25 high Treg占CD4+T细胞的比例为4.40%±0.26%,明显低于对照组(8.56%±0.36%,P<0.01);而术后13、60d抗体组CD4+CD25 high Treg所占比例分别为7.00%±0.47%、3.75%±0.19%,与对照组(分别为8.04%±0.32%、3.66%±0.31%)比较差异无统计学意义(P>0.05)。抗体组CD25 mRNA相对表达水平在给予第二次抗体前(术后第13天)为1.65±0.22,术后第17天为1.84±0.27,两者间差异无统计学意义(P>0.05)。对照组术后第17天CD25 mRNA相对表达水平为1.70±0.23,与抗体组比较差异无统计学意义(P>0.05)。结论两剂共100mg抗CD25单抗仅一过性地降低CD4+CD25 high Treg,不会影响其活化扩增,无损于术后早期的免疫耐受诱导及维持。
基金This project was supported by grants from National Science Fundation for Distinguished Young Scholars (No. 30225038) The National Basic Research Program(No.2001CB5101).
文摘The proportion and changes of CD4^＋CD25^high regulatory T cells （Trs） in peripheral blood of non-small cell lung cancer （NSCLC） patients were analyzed and their clinical significance explored. The peripheral blood was collected from 61 patients with NSCLC and 15 healthy controls. By using monoclonal antibodies, the blood samples were evaluated with the flow cytometry for lymphocyte subsets （CD3^＋, CD4^＋ and CD8^＋） and CD4^＋CD25^high Tr cells. The results showed that the proportion of CD4^＋CD25^high Tr cells in NSCLC group was significantly higher than in control group [（4.36 ±2.07） % vs （2.04±1.03） %, P〈0.01]. The proportion of CD4^＋CD25^ high Tr cells in late stage was higher than that in early stage [stages Ⅰ ＋Ⅱ （2.264±0.6） %; stage Ⅲ（3.284± 1.38） %; stage IV （6.06 4±4.08） %] （P〈0.05）. Kaplan-Meier survival analysis revealed that the prognosis of the patients who had higher proportion of CD4^＋CD25^high Tr cells in peripheral blood was worse （P=0.0026）. In conclusion, the relative increase in CD4^＋CD25^high Tr cells in peripheral blood may be related to im- munosuppression and tumor progression in patients with NSCLC. This finding suggests that CD4^＋CD25^high Tr cells in peripheral blood of NSCLC may be positive for prognosis analysis. The use of depletion of the CD4^＋CD25^high Tr cell therapy to treat NSCLC patients may be an effective strategy.
